Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment
Open Access
- 13 June 2018
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 10 (6) , e2798
Abstract
There are many novel chemotherapeutic options and targeted therapies available for the treatment of colorectal and pancreatic cancer. Patients with these cancers often have hepatic impairment either from the metastasis to the liver or from the chemotherapy or targeted therapies used to treat the disease. It is important to describe the effects of these agents in patients with hepatic impairment. This article will review the dosage recommendations for the chemotherapy regimens and targeted therapies in colorectal and pancreatic cancer patients in the setting of hepatic impairment.Keywords
This publication has 13 references indexed in Scilit:
- Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group StudyClinical Therapeutics, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Toxicities of Gemcitabine in Patients with Severe Hepatic DysfunctionAnnals of Pharmacotherapy, 2010
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005
- Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunctionAnnals of Oncology, 2003
- Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic DysfunctionJournal of Clinical Oncology, 2002
- Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565Journal of Clinical Oncology, 2000
- Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.1999